

**Drug Utilization Review Board
Meeting Minutes
April 26, 2019
9:00 a.m.**

**John H. Winters Human Service Complex Public Hearing Room
701 West 51st
Austin, TX 78751**

Table 1: Drug Utilization Review Board member attendance at the Friday, April 26, 2019 meeting.

MEMBER NAME	YES	NO	MEMBER NAME	YES	NO
Dr. James Barnes	X		Dr. Alejandro Kudisch	X	
Dr. Scott Blaszczyk	X		Dr. Mark D. Lacy	X	
Mr. Dennis Borel	X		Dr. Kim Pham		X
Dr. Deborah Briggs	X		Dr. Jill Lester	X	
Dr. Oscar Brown	X		Dr. Thanhhao Ngo		X
Dr. Deeatra Craddock	X		Dr. Richard Noel	X	
Dr. Salil Deshpande	X		Dr. Joseph Vazhappilly	X	
Dr. Jennifer Fix	X		VACANT		
Dr. Robert Hogue	X		VACANT		
Dr. Summer Keener		X	VACANT		

Table 2: Drug Utilization Review Board state agency staff attendance at the Friday, April 26, 2019 meeting.

STATE AGENCY STAFF NAME	YES	NO	STATE AGENCY STAFF NAME	YES	NO
Dr. Mitchel Abramsky	X		Joshua Dominguez, PharmD	X	
Aaliya Ahmad, PharmD	X		Gina Marie Muniz, CBCP		X
Nahid Assadi, RPh	X		Arshad Qureshi, PharmD	X	
Louisa Cevera		X	Cynthia Galindo, CPh.	X	
Maribel O. Castoreno	X				

Table 3: Drug Utilization Review Board contractor attendance at the Friday, April 26, 2019 meeting.

CONTRACTOR NAME	YES	NO	CONTRACTOR NAME	YES	NO
Chris Andrews, Pharm.D. (Magellan Medicaid Administration)	X		Matthew Lennertz, Pharm.D. (Magellan Medicaid Administration)	X	
Larry Dent Pharm.D., (Conduent)	X		Jennifer Seltzer, Pharm.D. (University of Texas College of Pharmacy)	X	
Christina Faulkner, Pharm.D. (Health Information Designs, LLC.)	X				

Agenda Item 1: Call to Order

Dr. Robert Hogue called the meeting to order at 9:00 a.m. Dr. Hogue introduced and turned the floor over to Ms. Stephanie Gutierrez, HHSC, Advisory Committee Coordination Office. Ms. Gutierrez read meeting logistics and conducted roll call. Ms. Gutierrez noted there was a quorum.

Agenda Item 2: Approval of minutes from January 25, 2019

Ms. Gutierrez reminded members a copy of the DRAFT minutes were sent by email. Ms. Gutierrez asked if there were any necessary changes. Hearing none, Ms. Gutierrez requested a motion.

MOTION: Dr. James Barnes motioned to approve the January 25, 2019 minutes with Dr. Oscar Brown seconding the motion. A voice vote was taken and the motion carried unanimously with no objections nor abstentions.

Agenda Item 3: New Business

Dr. Hogue opened the floor to public comment on the drug classes on the therapeutic and clinical drug review for the Medicaid Preferred Drug List. Ms. Gutierrez read Public Comment Announcements to members of the Board and members of the audience.

Dr. Hogue reviewed the classes of drugs for public comment. The following individuals provided testimony to the Board and answered questions.

Dr. Hogue announced a 10-minute break at 10:34 a.m. to 10:44 a.m. Dr. Hogue reconvened the meeting at 10:45 a.m.

Speaker	Representing	Recommendations	PDL Class
Robert Martin	Insmed	Arikayce	Antibiotics, Inhaled
Shannon Sands	Janssen	Xarelto	Anticoagulants
Mical De Brow	Boehringer Ingelheim	Pradaxa	Anticoagulants
Maria Posey	Pfizer	Eliquis	Anticoagulants
Jamie Gomez	Self	Eliquis	Anticoagulants
Nikkilina Crouse	Adamas Pharma	Gocovri	Antiparkinsons Agents
Emily Croce	Dell Children's Medical Group	Hemangeol	Beta Blockers
Linda Shannon	Vascular Birthmark Foundation	Hemangeol	Beta Blockers
Sarah McAloon	Self	Hemangeol	Beta Bloackers
Mical De Brow	Boehringer Ingelheim	Spiriva, Stiolto	COPD Agents
Kirsten Mar	AstraZeneca	Bevespi	COPD Agents
Daniel Ting	Pfizer	Xeljanz, Inflectra	Cytokine and CAM Antagonists
Kevin Duhrkopf	Sanofi	Kevzara	Cytokine and CAM Antagonists
Gia McLean	Celgene	Otezla	Cytokine and CAM Antagonists
Shannon Sands	Janssen	Tremfya	Cytokine and CAM Antagonists
Mai Duong	Novartis	Cosentyx	Cytokine and CAM Antagonists
Sylvia Churchill	Amgen	Enbrel	Cytokine and CAM Antagonists
Bethany Boyd	Pfizer	Retacrit	Erythropoiesis Stimulating Proteins
Angela Haynes	Pharming Healthcare	Ruconest	HAE Treatments
PJ Arnold	Takeda	Takhzyro	HAE Treatments
John Williamson	U.S.H.A.E.A.	Open Access	HAE Treatments

Speaker	Representing	Recommendations	PDL Class
Mical De Brow	Boehringer Ingelheim	Jardiance	Hypoglycemics, SGLT2
Shannon Sands	Janssen	Invokana	Hypoglycemics, SGLT2
Chasity Lynch	Self	Invokana	Hypoglycemics, SGLT2
Kirsten Mar	AstraZeneca	Xigduo XR	Hypoglycemics, SGLT2
Sylvia Churchill	Amgen	Repatha	Lipotropics, Other
Taeyo Chestley	Medicure, Inc	Zypitamag	Lipotropics, Statin
Elizabeth Esterl	United Therapeutics	Orenitram	PAH Agents
Tari Garza	Actelion	Opsumit, Uptravi	PAH Agents
Bennie McWilliams	Self	Open Access	Pancreatic Enzymes
Matt Phillips	Cerecor	Poly-Vi-Flor, Tri-Vi-Flor	Pediatric Vitamins
Crystal Kaczmar	Emmaus Life Sciences	Endari	Sickle Cell Anemia Treatments
Christina Heiner	Medunik USA	Siklos	Sickle Cell Anemia Treatments
Tonya Prince	Sickle Cell Association of Houston	Endari	Sickle Cell Anemia Treatments
Jeffrey Meteer	Dova Pharmaceuticals	Doptelet	Thrombopoiesis Stimulating Proteins

Agenda Item 4: Public comment on new drugs to be reviewed for the Medicaid Preferred Drug List (PDL)

Dr. Hogue opened the floor to public comment on the clinical drug reviews on new drugs to be reviewed for the Medicaid PDL.

Dr. Hogue reviewed the classes of drugs for public comment. The following individuals provided testimony to the Board and answered questions.

Speaker	Representing	Recommendations	PDL Class
Courtney Walker	Novo Nordisk	Tresiba Vial	Hypoglycemics, Insulin and Related Agents
Mauricio Rodriguez	Paratek Pharmaceuticals	Nuzyra Tablet	Tetracyclines

Members discussed:

- Data specific to efficacy of long acting NPH insulin versus Tresiba
- Advantages of Nuzyra® (omadacycline) versus tetracyclines

Agenda Item 5: Therapeutic and clinical drug reviews and updates

Dr. Hogue turned the floor over to Dr. Matt Lennertz, Magellan Medicaid Administration, MMA. Dr. Lennertz reviewed points of the classes that have not been brought up by Public Comment or previous meetings.

Agenda Item 6: Executive Work Session

Dr. Hogue announced the Board will go into closed session at 12:11 p.m. Dr. Hogue read the legislation granting the Board the ability to meet in executive session.

Agenda Item 7: Announcements of drugs recommended for the Medicaid PDL

Dr. Hogue reconvened the meeting from executive session at 2:17 p.m. Dr. Hogue turned the floor over to Dr. Lennertz. Dr. Lennertz reviewed, for the record, the proposed recommendations decided by the Board in executive session. Dr. Lennertz referenced the PowerPoint, *Texas Medicaid Drug Utilization Review Board April 26, 2019*.

Dr. Hogue requested a motion.

MOTION: Dr. James Barnes motioned to approve and accept the proposed recommended drug list. Dr. Alejandro Kudisch seconded. A voice vote was taken and the motion carried unanimously with no objections nor abstentions.

Agenda Item 8: Retrospective Drug Utilization Review (DUR)

Dr. Hogue introduced and turned the floor over to Dr. Larry Dent, Board Certified Pharmacotherapy Specialist, Conduent, LLC. Dr. Dent referenced the PowerPoint and handout, *Texas DUR Board Proposed Retrospective DUR Intervention*.

Agenda Item 8a: Report on recent retrospective DUR interventions

Dr. Dent covered the report of recent interventions:

- Proton Pump Inhibitors Drug Use Evaluation
- Appropriate Use of Antibiotics

Agenda Item 8b: Report on recent retrospective DUR intervention outcomes

Dr. Dent reported on recent outcome reports:

- Asthma Disease Management
 - An increase in savings attributed to promoting opportunities to add inhaled cortical steroids for controlled therapy
- Bipolar Disorder Management
- Hypertension Disease Management

Members discussed:

- Savings representing drug spend savings
- Dr. Dent stated Conduent can collect data pertaining to Emergency Room and Hospital visits to determine cost savings
- The numbers reported on the proposal include numbers for managed care organizations however the calculations are for fee for service patients only
- Adding a disclaimer that the data represents a certain percentage of the Texas population of fee for service patients and represents only the drug spend savings within this population
- Looking at data on whether money is being saved on drug spending or if it is being spent more at hospital visits

ACTION ITEM:

- Dr. Dent will discuss with his colleagues regarding providing a trending report.
- Dr. Dent will provide the methodology on how Conduent calculates outcome numbers.

Agenda Item 8c: Retrospective DUR Proposals

Dr. Dent proceeded with retrospective DUR proposals:

- Mental Health (MH) Disorders Management
 - The purpose is to promote safe and cost-effective prescribing of psychotropic drugs based on the following indicators:
 - extended duration of an antidepressants, both for single episode depression or bipolar disorder.
 - Duplicative antidepressants
 - Concurrent use of antidepressants and risk of serotonin syndrome
 - Prolonged use of benzodiazepines
 - Prolonged use of sedative/hypnotics

Members Discussed:

- Differentiating between single episode deprecation vs. multiple-episode will be through looking for several of ICD-10 code for depressive disorders and then looking as far back as possible for prior diagnosis.
- Patients on long acting injectable drugs may not need oral antipsychotic
- Children using benzodiazepines for aiding them with sleep
- Listing medications that are specific to the education only risks
- Individuals diagnosed with epileptic seizures or muscle disorders should also be flagged for chronic use of benzodiazepines because benzodiazepines are not first-line therapy for treating seizures. be allowed chronic therapy
- Anticonvulsant Drug Use Evaluation
 - The purpose for this intervention is to identify the following:
 - Anticonvulsants drug-drug interactions
 - Increased risk of adverse events with anticonvulsants
 - Anticonvulsant treatment adherence, and laboratory monitoring for potential anticonvulsant toxicities
 - Also, information material regarding concomitant use of certain anticonvulsants and contraceptives is included in the letter.

Members discussed:

- To include the names of anticonvulsants that cause decreased effects of contraceptives.
- This intervention targets anticonvulsant use for any indication, not just for the diagnosis of epilepsy.

- In addition to drug interaction with contraceptives, drug-drug interaction with anticoagulants should be included.
Anticonvulsants and bone density loss, also, to be added in the letter

MOTION: Dr. Barnes made a motion to approve the retrospective DUR proposals for MH disorders management. Dr. Scott Blaszczyk seconded the motion. A voice vote was taken and the motion carried unanimously with no objections nor abstentions.

MOTION: Dr. Mark D. Lacy motioned to approve the retrospective DUR proposals for anticonvulsant drug use with changes to the letter. Dr. Deborah Briggs seconded the motion. A voice vote was taken and the motion carried unanimously with no objections nor abstentions.

Agenda Item 9: Retrospective drug use, criteria for outpatient use in Vendor Drug Program

Dr. Hogue introduced and turned the floor over to Dr. Jennifer Seltzer, Pharm. D., University of Texas at Austin, College of Pharmacy. Dr. Seltzer the PowerPoint, *Texas Medicaid Vendor Drug Program Drug Utilization Review Board Meeting - Retrospective Drug Use Proposals*.

Dr. Seltzer presented on nine retrospective criteria sets updated for posting on the vendor drug webpage.

MOTION: Dr. Barnes motioned to approve the retrospective drug use criteria for outpatient use in Vendor Drug Program (VDP) for all categories. Dr. Lacy seconded the motion. A voice vote was taken and the motion carried unanimously with no objections nor abstentions.

Agenda Item 10: Prospective prior authorization proposals (clinical edits)

Dr. Hogue introduced and turned the floor over to Dr. Christina Faulkner, Pharm. D., Health Information Designs, LLC. Ms. Faulkner referenced the PowerPoint, *Texas HHSC DUR Board Meeting Prospective Prior Authorization Proposals*.

Agenda Item 10a. Arikayce (Amikacin liposome inhalation suspension) -new criteria

Dr. Faulkner presented clinical edits provided in the PowerPoint.

Members discussed:

- Adding a footnote as to where to find what constitutes the diagnostic criteria for Mycobacterium Avium Complex (MAC) Lung Disease
- Having a retrospective review on the number of patients that did or did not meet the criteria and were prescribed the medication
- The data provided by Dr. Faulkner does not include the rebate information

Dr. Hogue turned the floor over to Ms. Gutierrez to read public comment logistical announcements. Dr. Hogue opened the floor up to public testimony.

MOTION: Dr. Oscar Brown made a motion to approve the prospective prior authorization proposals for Arikayce. Dr. Lacy seconded the motion. A voice vote was taken and the motion carried unanimously with no objections nor abstentions.

Agenda Item 10b. Hereditary Angioedema (HAE)

Dr. Faulkner presented clinical edits provided in the PowerPoint.

MOTION: Mr. Dennis Borel made a motion to approve prior authorization proposals for Hereditary Angioedema. Dr. Lacy seconded the motion. A voice vote was taken and the motion carried unanimously with no objections nor abstentions.

Agenda Item 10c. Inhaled Antibiotics - new criteria

Dr. Faulkner presented clinical edits provided in the PowerPoint.

MOTION: Mr. Borel made a motion to approve prior authorization proposals for inhaled antibiotics. Dr. Brown seconded the motion. A voice vote was taken and the motion carried unanimously with no objections nor abstentions.

Agenda Item 10d. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Agents

Dr. Faulkner presented clinical edits provided in the PowerPoint.

MOTION: Dr. Brown made a motion to approve prior authorization proposals for Sodium-Glucose Cotransporter-2. Dr. Lacy seconded the motion. A voice vote was taken and the motion carried unanimously with no objections nor abstentions.

Agenda Item 10e. Urea Cycle Disorder Agents – new criteria

Dr. Faulkner presented clinical edits provided in the PowerPoint.

Members discussed:

- Receiving edification regarding the difference between criteria

MOTION: Dr. Lacy made a motion to approve prior authorization proposals for Urea Cycle Disorder Agents. Dr. Brown seconded the motion. A voice vote was taken and the motion carried unanimously with no objections nor abstentions.

Agenda Item 11: Adjournment

Dr. Hogue announced the next meeting will be on July 26, 2019 at 9:00 a.m. in the John H. Winters Public Hearing Room. Dr. Hogue adjourned the meeting at 3:59 p.m.

The webcasting link is: <https://texashsc.swagit.com/play/04262019-781>